1. Home
  2. VS vs CALC Comparison

VS vs CALC Comparison

Compare VS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versus Systems Inc.

VS

Versus Systems Inc.

N/A

Current Price

$0.74

Market Cap

7.9M

Sector

Technology

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

N/A

Current Price

$1.21

Market Cap

7.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VS
CALC
Founded
2013
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.6M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
VS
CALC
Price
$0.74
$1.21
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $38.00
AVG Volume (30 Days)
12.3K
★ 62.6K
Earning Date
11-24-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 75.97
N/A
EPS
★ N/A
N/A
Revenue
★ $2,183,415.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3711.30
N/A
52 Week Low
$0.70
$0.44
52 Week High
$1.86
$72.00

Technical Indicators

Market Signals
Indicator
VS
CALC
Relative Strength Index (RSI) 31.82 41.27
Support Level N/A $1.08
Resistance Level $1.18 $1.84
Average True Range (ATR) 0.08 0.22
MACD -0.01 0.02
Stochastic Oscillator 15.14 8.81

Price Performance

Historical Comparison
VS
CALC

About VS Versus Systems Inc.

Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: